You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
希玛眼科(03309.HK)拟900万港元收购希华检测90%股权
格隆汇 02-09 21:07

格隆汇 2 月 9日丨希玛眼科(03309.HK)宣布,于2021年2月9日,公司全资附属公司希玛检测拟向林顺潮及李肖婷收购希华检测90%股权,总代价为现金900万港元。

据悉,希华检测主要从事提供医学实验室服务。其为香港政府认可的本地COVID-19核酸检测机构之一,并已于2020年12月取得香港认可处(HKAS)的香港实验所认可计划(HOKLAS)认证。目前,希华检测配备有一只由合资格医疗及实验室人员组成的团队,还拥有本身的实验室设备。希华检测于取得香港实验所认可计划(HOKLAS)认证后,已于2021年1月投入商业运营。紧接收购事项前,希华检测分别由执行董事兼控股股东林顺潮及李肖婷拥有85%及15%权益。

公告称,董事会认为,收购事项将与集团现有服务相得益彰,并将提升集团作为综合医疗服务供应商的医疗服务。董事会认为,收购事项符合集团的发展策略,对集团而言乃属策略性投资机会。于收购事项后,集团可进一步将希华检测的服务范围拓展至其他医学实验室检测服务(包括但不限于眼科)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account